Treatment of Recurrent or Metastatic Uterine Adenosarcoma
Table 1
Patient characteristics.
Variable
Patients with recurrence, no. of patients (%)
Age, median (range)
55 years (27 to 79 years)
Race
Caucasian
63 (80.8%)
African American
10 (12.8%)
Hispanic
5 (6.4%)
ECOG performance status
0
17 (21.8%)
1
30 (38.5%)
Unknown
31 (39.7%)
Presenting symptoms
Abnormal uterine bleeding
35 (44.9%)
Pelvic pain
13 (16.7%)
Incidental finding
4 (5.1%)
Other
6 (7.7%)
Unknown
20 (25.6%)
Size, median (range)
7.1 cm (0.4 to 25 cm)
≤5 cm
14 (17.9%)
>5 cm
36 (46.2%)
Unknown
28 (35.9%)
Myometrial invasion
No myometrial invasion
12 (15.4%)
≤½ of myometrium
26 (33.3%)
>½ of myometrium
8 (10.3%)
Unknown
32 (41.0%)
Sarcomatous overgrowth
Absent
15 (19.2%)
Present
58 (74.4%)
Unknown
5 (6.4%)
Lymph node involvement
None
34 (43.6%)
Present
1 (1.3%)
No lymph node sampling
39 (50.0%)
Unknown
4 (5.1%)
Uterine adenosarcoma FIGO stage at diagnosis
Ia
7 (9.0%)
Ib
19 (24.4%)
Ic
4 (5.1%)
I (nos.)
9 (11.6%)
IIa
7 (9.0%)
IIb
12 (15.4%)
IIIa
7 (9.0%)
IIIb
4 (5.1%)
IIIc
1 (1.3%)
IVa
4 (5.1%)
IVb
1 (1.3%)
Unknown
3 (3.8%)
Tumor location
Uterine corpus
58 (74.4%)
Ovary
5 (6.4%)
Cervix
2 (2.6%)
Pelvic primary
11 (14.1%)
Vagina
1 (1.3%)
Unknown
1 (1.3%)
Initial treatment strategy
Surgery alone
45 (57.7%)
Surgery + radiation (adjuvant or neoadjuvant)
22 (28.2%)
Surgery + chemotherapy (adjuvant or neoadjuvant)
6 (7.7%)
Surgery + radiation + chemotherapy
4 (5.1%)
Surgery + hormonal therapy
1 (1.3%)
Bilateral salpingo-oophorectomy
Yes
55 (70.5%)
No
13 (16.7%)
History of prior BSO
9 (11.5%)
Unknown
1 (1.3%)
Lymphadenectomy
Yes
31 (39.7%)
No
43 (55.1%)
Unknown
4 (5.1%)
Vital status
Alive
24 (30.8%)
Dead
54 (69.2%)
Recurrence
Any recurrence
78
Local (abdomen/pelvis)
61 (78.2%)
Local and distant
11 (14.1%)
Distant
5 (6.4%)
Unknown
1 (1.3%)
Median follow-up
8.2 years
This table described patient demographics (age and race), presenting symptoms, performance status, tumor pathologic characteristics (size, myometrial invasion, sarcomatous overgrowth, and lymph node involvement), tumor stage, tumor location, initial treatments (surgery, radiation, chemotherapy, BSO, and lymphadenectomy), vital status (alive versus dead), and recurrence location for patients with recurrence.
